How Peer-Driven Feedback Is Reshaping Healthcare Technology Purchasing Decisions
Healthcare buyers are moving away from vendor‑centric demos toward peer‑driven feedback when evaluating digital health platforms. Executives now prioritize real‑world implementation insights, workflow integration, and user experience over feature lists and AI hype. This shift comes as hospitals grapple with staffing shortages, rising implementation costs, and the need for seamless interoperability across complex tech ecosystems. Peer‑based evidence is becoming a decisive factor in multi‑billion‑dollar digital transformation budgets.
Rural Hospital Closures Disrupt Care Access for Injured Workers but Don’t Worsen Claim Outcomes
A Workers Compensation Research Institute study of more than 12 million claims across 29 states found that rural hospital closures cut same‑day emergency care use by 3.6 percentage points and added an average of 10.5 miles to travel distance. The impact was...
Novartis Reveals More Data Behind Pluvicto Expansion Bid
Novartas reported new PSMAddition trial data showing that adding its radioligand therapy Pluvicto to standard hormonal treatment cuts PSA progression by 58% in hormone‑sensitive metastatic prostate cancer. Deep PSA reductions below 0.2 ng/mL were achieved by 87.4% of patients versus 74.9%...
Amgen’s Rare Disease Drug Tavneos Tied to 20 Deaths in Japan
Amgen’s rare‑disease drug Tavneos has been linked to 20 deaths among roughly 8,500 Japanese patients, primarily due to vanishing bile duct syndrome, a severe form of drug‑induced liver injury. The Japanese distributor Kissei Pharmaceutical has warned doctors against initiating new...
10 Key Lessons in 'the Shift From CoPilots to Agents in Healthcare'
Healthcare is moving from reactive AI copilots to autonomous agents that can execute multi‑step clinical workflows with minimal human input. Global AI spending is projected to hit $2.52 trillion in 2026, while AI firms secured $242 billion in Q1 2026, fueling rapid adoption...
Harbour Posts Preclinical Data on Would-Be Rival to Eli Lilly’s $1.9B Obesity Bet
Harbour BioMed released preclinical data on LET003, an ACVR2A/2B‑targeting monoclonal antibody created with its AI‑enabled Hu‑mAtrIx platform. In mouse and monkey studies the molecule cleared more slowly than comparators and drove a 13.5% increase in lean mass versus a rival...
Reminder Texts Help Radiology Department Reduce Nuclear Medicine Appointment Cancelations
Automated reminder texts introduced by the Mayo Clinic in Jacksonville have cut cancellations for nuclear medicine exams. In a study published in JACR, opening the messages lowered stress‑test cancellations to 3.21% versus 5.91% overall, and FDG PET cancellations fell to...
The Next AI Use Case in Radiology Isn’t Diagnosis. It’s Patient Understanding
Peter Nemeth argues that the first scalable AI use case in radiology is not autonomous diagnosis but patient‑focused explanation of imaging results. The 21st Century Cures Act now forces health portals to release reports instantly, leaving most patients confused by...
Sandoz Reports the EC Approval of Bysumlog and Dazparda (Biosimilars, Humalog and NovoRapid)
The European Commission has granted approval for Sandoz's biosimilar insulin pens Bysumlog (insulin lispro) and Dazparda (insulin aspart). Both products are authorized as prefilled pens for diabetes treatment in adults, children and patients as young as one year, demonstrating efficacy...
Hospital Cyber Attacks Are Increasingly Hitting Patient Care
European hospitals are facing a dramatic shift in cyber risk, with 82 % rating the threat as extreme and 74 % expecting a major incident this year. Attackers now target authentication, clinical workflows and digital patient‑care pathways, turning cybersecurity into a direct...
BIO Supports and Seeks Refinements to FDA’s Plausible Mechanism Framework
The FDA has issued draft guidance introducing a Plausible Mechanism Framework to evaluate safety and efficacy of individualized, disease‑targeted therapies when traditional trials are infeasible. The Biotechnology Innovation Organization (BIO) issued a supportive comment letter, praising the agency’s direction while...
We Need to Domesticate Africa’s Health Algorithm
The article argues that Africa must domesticate its health‑data AI ecosystem to capture economic and public‑health value. While the continent boasts some of the world’s most diverse and under‑represented health data, less than 1% of global data‑center capacity and 70‑90%...
Supercharging Immune Cells May Help Control HIV Long-Term
Scientists have repurposed CAR‑T cell therapy, originally used for cancer, to target HIV. In a small Phase 1 trial, two participants who received the engineered T cells remained off antiretroviral drugs with undetectable viral loads for nearly two years and one...
AstraZeneca Reports the US FDA Approval of Baxfendy (Baxdrostat) To Treat Hard-to-Control Hypertension
AstraZeneca’s Baxfendy (baxdrostat) received U.S. FDA approval for use with other antihypertensives in patients with uncontrolled or treatment‑resistant hypertension. The approval is based on the Phase III BaxHTN trial, which enrolled 796 participants and showed significant blood‑pressure reductions versus placebo. In...
Tracy Beth Høeg Ousted From FDA in Wider Senior Leadership Shakeup
Tracy Beth Høeg was dismissed after just six months as acting head of the FDA’s Centre for Drug Evaluation and Research (CDER), marking the fifth leadership change at the unit since President Trump’s second term began. During her brief tenure, Høeg pushed...
Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF
Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by Japan’s Ministry of Health, Labour and Welfare for treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B inhibitor with antifibrotic and immunomodulatory properties to receive such...
Efgartigimod Approved for Seronegative Myasthenia Gravis Patients
The FDA has expanded approval of efgartigimod alfa‑fcab (Vyvgart) to treat adults with acetylcholine‑receptor‑antibody‑negative generalized myasthenia gravis, making it the first FcRn‑targeted therapy for this underserved group. The decision follows the phase 3 ADAPT SERON trial, which enrolled 119 seronegative patients and...
How to Tackle the Chronic Condition Trifecta
Cardiovascular disease, obesity and diabetes affect roughly 130 million U.S. adults, with over half reporting multiple chronic conditions. Traditional, siloed wellness programs have failed to curb the escalating health‑care costs and productivity losses tied to this trifecta. Brokers and benefits leaders...
Insurers’ Delays in Approving Medical Care Persist, Despite Promises
Nearly a year after insurers pledged to overhaul prior authorization, patients and doctors report that delays and denials remain commonplace. A KFF poll shows 70% of insured adults find the process burdensome, with one‑third calling it a major obstacle. Insurers...
Why Patients Feel the Difference in an Automated Practice (Even if They Don’t Know It)
Healthcare providers are investing heavily in automation, but patients don’t notice the technology itself—they notice the smoother experience it creates. By automating scheduling, intake, communication and post‑visit follow‑through, practices eliminate friction points that traditionally caused delays and confusion. The result...
Emergency Medicine Revenue at Risk: Navigating the Algorithmic Squeeze
Emergency medicine groups are confronting a new wave of payer pressure driven by automated, opaque algorithms that downcode claims based on final diagnoses. Recent coding guideline changes in 2023 shifted billing emphasis to medical‑decision‑making, inflating acuity levels and prompting payers...
Reinventing the Stethoscope and Cardiopulmonary Care
Eko Health, backed by Infineon, has launched the CORE 500 AI‑powered digital stethoscope, which pairs ultra‑low‑power PSoC 63 microcontrollers with advanced MEMS microphones to deliver real‑time heart‑sound analysis and three‑lead ECG. Clinical data from the TRICORDER trial show the device identifies heart...
Nursing Staff Levels Endangering Patients, Says Union
A Royal College of Nursing (RCN) survey reveals that 79% of frontline nurses see rising clinical complexity while only one in ten believe staffing levels are adequate. Seventy‑nine percent report heightened risk to patients, and 69% say they must constantly...
Lotte Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
Lotte Biologics announced on May 18, 2026 an expanded collaboration with South Korean biotech Ottimo Pharma to manufacture its PD‑1/VEGFR2 dual‑paratopic antibody, OTP‑01. The agreement builds on a June‑2025 deal and adds commercial process development support at Lotte’s Syracuse Bio Campus in...
PainTEQ Announces US Launch of SI Joint Implant
PainTEQ has begun commercial sales of TRAQ, a posterior sacroiliac (SI) joint fusion implant, in the United States. The device features triangular barbs that achieve bicortical fixation of the sacral and iliac cortices and is delivered through a 1‑inch posterior...
Genentech Reports FDA Approval of Tecentriq and Tecentriq Hybreza for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Genentech’s Tecentriq and Tecentriq Hybreza received FDA approval as adjuvant therapies for adults with muscle‑invasive bladder cancer (MIBC) who show circulating tumor DNA (ctDNA) minimal residual disease after cystectomy. The approval is linked to Natera’s Signatera CDx assay, which was...
WHO Kicks Off Annual Assembly Amid Hantavirus, Ebola Crises
The WHO’s annual decision‑making assembly opened in Geneva on May 18 while the organization grapples with a rare hantavirus outbreak on a cruise ship and a fresh Ebola flare‑up in the Democratic Republic of Congo. At the same time, the United...
Makary’s Successor Faces Tough Task Managing FDA Amid Budget Cuts
Marty Makary was removed as FDA commissioner after just over a year, amid criticism over his positions on flavored vapes and abortion pills. The Trump administration has proposed a $7 bn, 5.5% cut to the FDA budget for FY2026, shrinking staff...
AstraZeneca and Daiichi Sankyo’s Enhertu Receives US FDA Approval in Early Breast Cancer for Two Indications
The U.S. FDA approved AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Enhertu (trastuzumab deruxtecan) for two early‑stage HER2‑positive breast‑cancer indications. In the neoadjuvant setting, Enhertu combined with trastuzumab‑pertuzumab (THP) earned approval after the DESTINY‑Breast11 trial showed a 67.3% pathologic complete response...
What You Need to Know About the Ebola Outbreak that Has the WHO Concerned
The World Health Organization has declared the Ebola outbreak in the Democratic Republic of Congo and Uganda a public health emergency of international concern. To date, 336 people have been infected and 88 have died, with the rare Bundibugyo strain...
Can Revolution’s 'Miracle' Pancreatic Cancer Drug Be Topped? Immuneering, Actuate Say Yes
Revolution Medicines reported Phase 3 data showing its oral RAS inhibitor daraxonrasib more than doubled median overall survival for advanced pancreatic cancer to 13.2 months versus 6.7 months on chemotherapy. The results triggered a 40 % share surge and will support global regulatory filings,...
Simple Field-Based Muscular Strength Tests that Predict Your Future Health
A new systematic review and meta‑analysis of 155 cohort studies confirms that two simple field‑based strength tests – handgrip strength and the 5‑repetition chair‑stand – reliably predict a wide range of future health outcomes. Adults in the highest grip‑strength quartile...
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M
MannKind Corp. posted Q1 2026 revenue of $90.2 million, a 15% rise year‑over‑year, driven by $15.5 million in Furoscix sales and higher Tyvaso DPI royalties. R&D expenses jumped 56% to $17.2 million and SG&A surged 116% to $54.1 million after acquiring scPharma and preparing for...
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
Palisade Bio reported Q1 2026 results, with research and development expenses climbing to $6.4 million, up from $1.0 million a year earlier. The rise reflects higher staffing, chemistry, manufacturing, and clinical trial costs for its lead candidate PALI-2108. The company...
Heart Valve Surgery Recovery: What To Expect
Heart valve replacement—either surgical (SAVR) or transcatheter (TAVR)—offers a high success rate but requires a structured recovery. SAVR patients typically spend 3‑7 days in the hospital and need four to six weeks for initial healing, while TAVR patients may go...
Here’s When (and Why) You Might Need Surgery or TAVR for Severe Aortic Stenosis
Severe aortic stenosis is treated by replacing the narrowed valve, either through surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). Physicians base the decision on three criteria: valve area under 1 cm², heart’s functional response (ejection fraction and...
This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’
Duracyte, a Rice‑University spin‑out, is developing an implantable "cell factory" that produces therapeutic proteins inside patients, eliminating the need for traditional biologic manufacturing and injection pens. The capsule‑sized device houses genetically engineered human cells, supplies them with nutrients from the...
Algorae Pharmaceuticals Expands AI Drug Combination Pipeline with Multi-Anchor AOS2 Program
Algorae Pharmaceuticals announced the completion of the prediction‑generation phase of its multi‑anchor drug‑combination program, leveraging the AlgoraeOS v2 (AOS2) AI platform. The effort produced in‑silico synergy forecasts for 18 anchor drugs across thousands of approved and investigational compounds, covering more...
AI-Driven Wearable Patches Help Identify Undetected Hormone Disruption in Unexplained Infertility
Researchers unveiled an AI‑enabled wearable skin patch that continuously monitors reproductive hormone levels and rhythms, revealing hidden endocrine disruptions in both men and women. In a study of 102 men with normal morning testosterone, the patch detected abnormal testosterone patterns...
Subjecting AI to Human Doctor Standards?
Flinders University researchers argue that AI models matching or outperforming physicians on text‑based diagnostic tasks should be judged by real‑world patient outcomes rather than benchmark scores. A recent *Science* study demonstrated AI’s parity with doctors on clinical vignettes and emergency‑department...
Hong Kong's eHealth Push Reaches Seniors, but App Use Lags
Hong Kong has enrolled 94% of its senior population—about 1.68 million people—in the citywide eHealth system, yet fewer than half (46%) have downloaded and activated the eHealth mobile app. The government responded with a new “Lite Mode” interface, on‑site support stations,...
AI Tool in Radiotherapy Advances Global Fight to Eradicate Cervical Cancer
A collaborative consortium has launched an AI‑driven radiotherapy planning platform that automates contouring and dose‑optimization for cervical cancer. Trained on more than 10,000 patient scans, the tool generates treatment plans in minutes, cutting planning time by roughly 40% while preserving...
AI Tool for Radiotherapy Can Support the Global Effort to Eliminate Cervical Cancer
An AI‑driven radiotherapy planning tool demonstrated high‑quality results in the multinational ARCHERY trial, achieving over 95% success for cervical cancer and 85% for prostate cancer. The technology compresses planning from weeks to roughly one hour, directly addressing specialist shortages that...
Intervention Improves Quality of Life in Young Adults with Cancer
A randomized trial of the Bright IDEAS‑YA program showed that six one‑on‑one problem‑solving sessions reduced depression and anxiety and improved health‑related quality of life among 344 young adults with cancer. At six months, participants experienced statistically significant gains of 3.23...
Campaigners Threaten Legal Action over UK-US Deal on Prices NHS Pays for Drugs
Campaign groups Global Justice Now and Just Treatment are threatening a judicial review after the UK government introduced a statutory instrument that allows the health secretary to over‑rule NICE’s drug‑pricing recommendations. The move is part of a broader UK‑US medicines...
STAT+: U.K. Advocacy Groups Threaten Court Action over a Key Provision in the Pharma Trade Deal with the U.S.
The United Kingdom and United States finalized a pharma‑trade agreement that grants the U.K. tariff‑free access to the U.S. market for at least three years. In exchange, Britain pledged to raise its medicines spending to 0.35% of GDP by 2028...
Weight-Loss Drugs Tied to Lower Death, Recurrence Risk After Breast Cancer
A retrospective cohort study of more than 840,000 breast‑cancer patients diagnosed between 2006 and 2023 found that use of GLP‑1 receptor agonists—drugs approved for type‑2 diabetes and obesity—was associated with a lower risk of death and cancer recurrence over a...
The Government Plans to Tighten NDIS Eligibility. Here’s What’s Likely to Change
Australia's government is set to tighten eligibility for the National Disability Insurance Scheme (NDIS) through legislation introduced by Health Minister Mark Butler. The bill grants the minister authority to cut funding across entire support categories, replaces medical‑diagnosis eligibility with a...
Mitochondria‐Targeted Zwitterionic Nanogels Trigger Photopyroptosis for Enhanced Cancer Therapy
Researchers have engineered zwitterionic PODMMA nanogels that naturally home to mitochondria, eliminating the need for additional targeting ligands. When loaded with the photosensitizer temoporfin, the nanogels deliver the drug directly to mitochondrial membranes and, upon 640 nm laser activation, generate a...
New Study Explores Erectile Dysfunction Risk Associated With Low-Dose Finasteride Use
Researchers presented at the 2026 American Urological Association meeting a large propensity‑matched cohort study of more than 10,000 men aged 18‑45 that links low‑dose (1 mg) finasteride, commonly prescribed for androgenetic alopecia, to a higher incidence of new‑onset erectile dysfunction at...